How long should you continue taking Ripotinib?

Repotrectinib is a selective tyrosine kinase inhibitor (TKI) targeting ROS1 and TRK gene rearrangements. It is mainly suitable for patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) and solid tumors with NTRK gene fusion. Tumors driven by such genetic mutations have attracted increasing attention globally, and targeted therapy has become one of the core strategies for controlling such cancers. As a precision treatment drug that targets multiple oncogenic fusion genes, Ripotinib has demonstrated good tolerability and durable efficacy in international multi-center studies.

In terms of duration of use, there is currently no unified and fixed treatment endpoint for reprotinib. According to its mechanism of action and clinical use principles, this drug is usually set as a continuous-use targeted drug, that is, patients need to take it for a long time until disease progression occurs, adverse reactions are intolerable, or the doctor determines that the drug can be discontinued based on evaluation. Different from short-term chemotherapy cycles, repotinib is more suitable as a chronic management drug for continuous suppression to prevent cancer cells from reactivating.

In In patients with ROS1 fusion or NTRK fusion-positive patients, repotinib is often used for first-line treatment or subsequent treatment after resistance to previous generation TKIs. For patients who respond well to drugs, the taking time can often last for more than 6 months, or even more than 1 year. The specifics need to be dynamically adjusted based on imaging examinations and tumor markers. In international studies, some patients can achieve disease stabilization for 12 to 18 months or even longer after taking repotinib, which shows that the drug not only takes effect quickly but also has the potential for maintenance treatment.

It is worth reminding that patients need to be reviewed regularly during medication to evaluate tumor control and closely monitor potential side effects, such as dizziness, gastrointestinal reactions, orALT elevation. Clinicians may make dose adjustments based on tolerance to help patients achieve longer use periods.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html